close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

MDT

100.73

-0.34%↓

A

134.59

-3.08%↓

VEEV

221.99

-0.99%↓

HQY

84.34

-2.92%↓

NEOG

9.75

-2.01%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc
Search

Harmony Biosciences Holdings Inc

Avatud

SektorTervishoid

36.86 0.16

Osta

Hinna uuendus 23. jaan 2026, 20:17 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.63

Max

37.25

Põhinäitajad

By Trading Economics

Sissetulek

11M

51M

Müük

39M

239M

P/E

Sektori keskmine

11.426

89.037

Aktsiakasum

1.08

Kasumimarginaal

21.242

Töötajad

268

EBITDA

14M

73M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+21.83% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

24. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

399M

2.1B

Eelmine avamishind

36.7

Eelmine sulgemishind

36.86

Uudiste sentiment

By Acuity

34%

66%

115 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. jaan 2026, 21:55 UTC

Tulu

Capital One Financial Posts Higher 4Q Profit As Lending Increases

DJ

Loe

22. jaan 2026, 23:52 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

DJ

Loe

22. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

DJ

Loe

22. jaan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

DJ

Loe

22. jaan 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

DJ

Loe

22. jaan 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

22. jaan 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

DJ

Loe

22. jaan 2026, 22:37 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

DJ

Loe

22. jaan 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

DJ

Loe

22. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

22. jaan 2026, 21:44 UTC

Tulu

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

DJ

Loe

22. jaan 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

DJ

Loe

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

DJ

Loe

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

DJ

Loe

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

DJ

Loe

22. jaan 2026, 21:30 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

DJ

Loe

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One To Acquire Brex >COF

DJ

Loe

22. jaan 2026, 21:13 UTC

Tulu

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

DJ

Loe

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

DJ

Loe

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

DJ

Loe

22. jaan 2026, 21:10 UTC

Tulu

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

DJ

Loe

22. jaan 2026, 21:06 UTC

Tulu

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Rev $15.58B >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q EPS $3.26 >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Interest Margin 8.26% >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net $2.13B >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Adj EPS $3.86 >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Charge-Offs $3.8B >COF

DJ

Loe

22. jaan 2026, 21:05 UTC

Tulu

Intuitive Surgical 4Q EPS $2.21 >ISRG

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

21.83% tõus

12 kuu keskmine prognoos

Keskmine 43.75 USD  21.83%

Kõrge 55 USD

Madal 32 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

4

Osta

0

Hoia

1

Müü

Põhineb 5 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Pikk perspektiiv

Very Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

115 / 360 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Muud aktsiad sektorist

MDT

Medtronic PLC

100.73

↓-0.34%

A

Agilent Technologies Inc

134.59

↓-3.08%

VEEV

Veeva Systems Inc

221.99

↓-0.99%

HQY

HealthEquity Inc

84.34

↓-2.92%

NEOG

Neogen Corp

9.75

↓-2.01%
help-icon Live chat